<DOC>
	<DOCNO>NCT01495247</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , phase Ib/ II study ( two part ) patient locally advance metastatic HER2 negative breast cancer . The first part ( phase Ib ) investigate MTD / Recommended Phase 2 Dose ( RP2D ) combination therapy BEZ235 twice daily ( b.i.d . ) weekly paclitaxel use Bayesian model . When MTD/ RP2D establish second part ( phase II ) start . Phase II evaluate efficacy safety weekly paclitaxel alone compare weekly paclitaxel plus BEZ235 bid .</brief_summary>
	<brief_title>Phase Ib/II Trial BEZ235 With Paclitaxel Patients With HER2 Negative , Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria ( phase lb ) : Females Breast cancer histologically cytologically confirm , HER2 negative locally advanced metastatic confirm radiology ECOG performance status 0 1 Adequate bone marrow organ function Exclusion Criteria ( Phase lb ) : Previous treatment PI3K and/or mTOR inhibitor Symptomatic Central Nervous System ( CNS ) metastases Concurrent malignancy malignancy last 5 year prior start study treatment Wide field radiotherapy ≤ 28 day limit field radiation palliation ≤ 14 day prior start study drug Active cardiac disease ( e.g . LVEF less institutional low limit normal , QTcF &gt; 480 msec , unstable angina pectoris , ventricular , supraventricular nodal arrhythmia ) Inadequately control hypertension Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BEZ235 and/or paclitaxel Treatment start study treatment drug know risk induce Torsades de Pointes , moderate strong inhibitor inducer isoenzyme CYP3A4 , warfarin coumadin analogue , LHRH agonists Sensitivity paclitaxel treatment Uncontrolled diabetes mellitus Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>PI3K pathway</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>